和誉-B02256.HK)公布,旗下附属公司附属公司和誉医药,在今年4月25至30日于美国芝加哥举行的2025年美国癌症研究协会大会上,以壁报形式发布四项最新突破性的临床前研究结果。
该等研究成果包括EGFR exon20ins抑制剂ABSK112、PRMT5*MTA抑制剂ABSK131、pan-KRAS抑制剂ABK-KRAS-1,以及一项研究KRAS G12C抑制剂潜在耐药机制的研究成果。(js/w)
(港股报价延迟最少十五分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.